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Abstract 
Pulmonary hypertension continues 
to be a major cause of morbidity and 
mortaUty, despite new treatments. 
Since inhaled nitric oxide has been 
reported to be effective in some 
cases, we investigated using 
nebulized nitroglycerine to treat 
pulmonary hypertension in children 
with congenital heart disease. Four 
children (ages 6-72 months) with 
severe pulmonary hypertension 
secondary to congenital heart 
disease (all with membranous 
ventricular septal defect, undergoing 
cardiac catheterization) were given 
3 cc of nebulized normal saline over 
10 min as placebo contro~followed 
by nebulized nitroglycerine (20}lg/Kg 
in 3cc normal saline). Normal saline 
administration did not elicit any 
change, but nitroglycerine 
administration resulted in the 
following changes (mean ±SI; paired , 
statistics): systolic pulmonary artery; 
pressure from 68±8 to 53±6 at 10 min 
into treatment (P 0.006), mean 
pulmonary artery pressure 4 7±4 to 
38±4 (P 0.005), heart rate 131±8 to 
127±7 (P 0.13), systolic blood pressure 
85±8 to 88±3 (P 0. 7), mean blood 
pressure 59±6 to 63±4 (P 0.5). These 
results indicate that nebulized 
nitroglycerine may be an effective, 
easy to administer, inexpensive, and 
safe alternative for treatment of 
severe pulmonary hypertension in 
cbildren with congenital heart disease, 
especially in areas where other 
treatments such as extracorporeal 
membrane oxygenation or inhaled 
nitric oxide are inaccessible. 
Introduction 
Pulmonary hypertension (PHD 
continues to be a major cause of 
morbidity and mortality in the 
pediatric age group. One common 
cause of pulmonary hypertension is 
congenital heart disease, unless the 
congenital heart lesions are 
surgically corrected early in life (1). 
Conventional therapy with 
mechanical ventilation is not always 
effective and use of intravenously 
administered vasodilators is limited 
because of the systemic effects, 
such as hypotension. Extracorporeal 
membrane oxygenation (ECMO) 
can be effective, but it is invasive 
and not feasible in small hospitals 
and rural areas. The discovery of 
the endothelium-derived relaxing 
factor (EDRF, 2) and its identification 
as nitric oxide (NO, 3) made it 
potentially possible to use inhaled 
NO for treatment of persistent 
pulmonary hypertension. 
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Reports of beneficial effects of 
inhaled NO in infants with 
persistent PHT (4), as well as in 
children with congenital heart 
disease (CHD, 5), are promising. 
Delivery of inhaled NO, however, 
requires special equipment (5,6) 
and may also be toxic. 
Many rural areas in the U.S. and 
the world have no access to either 
ECMO or inhaled NO. 
Nitrovasodilators are believed to 
release NO during their metabolism 
(7) and thus their vasodilatory 
mechanism is similar to that of NO. 
In this study, we sought to 
determine if nebulized nitroglycerine 
(NTG) can be effective in reducing 
pulmonary artery pressure without 
significant change in systemic BP in 
children with pulmonary 
hypertension secondary to CHD. 
Methods 
This study was approved by the 
Research Administration at Zhejiang 
Medical University Children's 
Hospital and consent was obtained 
for each of the four children, ages 6 
months to six years. These children 
were spontaneously breathing with 
uncorrected ventricular septal defect 
and severe PHT undergoing 
diagnostic cardiac catheterization. 
Severe pulmonary hypertension 
was defined as pulmonary artery 
pressure at least half of systemic 
blood pressure (Table 1). Baseline 
pulmonary artery pressure, systemic 
blood pressure, oxygen saturation, 
and heart rate were measured. Each 
patient received 3 cc of nebulized 
normal saline (NS) as placebo 
control and these vital signs were 
recorded at 5 min intervals. 
Next, each patient received a 
dose of 20 g per kilogram body 
weight of NTG in total volume of 3 
cc NS nebulized and their vital signs 
were recorded at 5 min intervals. 
Results 
Nebulized NS failed to produce 
any changes in any of the patients. 
Nebulized NTG, on the other hand, 
significantly reduced pulmonary 
artery pressure without changing the 
systemic BP or heart rate (Table 2). 
This study was terminated at the 
end of the catheterization procedure 
with no long-term follow-up. 
Discussion 
Treatment for severe PHT 
continues to be difficult and often is 
not successful, despite the promising 
role of nebulized NO and ECMO as 
well as other treatment modalities. 
The fact that the mechanism of 
action of nitrovasodilators involves 
metabolism to NO led us to 
investigate of their potential. 
To study the potential benefits of 
nebulized NTG on PHT, we selected 
four stable patients undergoing a 
diagnostic procedure. The lack of 
effect of NS eliminated the possibility 
of a placebo effect when using NTG. 
The significant reduction of both 
systolic and mean pulmonary artery 
pressures is encouraging, knowing 
that patients with uncorrected VSD 
tend to have sustained high diastolic 
pressure which would not respond 
well to any treatment. 
Administering nebulized NTG had 
no effect on systemic BP or heart rate, 
presumably because of the fast local 
metabolism and short half-life. This 
finding is also promising because of 
the limitations of any treatments 
associated with systemic effects. 
Conclusion 
Nebulized NTG appears to be an 
effective, easy to administer, 
inexpensive and safe alternative for 
treatment of severe PHT in children 
with CHD, especially in areas where 
other treatment modalities such as 
ECMO or inhaled NO are inaccessible. 
Larger studies on similar patients 
;md also on patients with different 
etiologies are needed to confirm 
our preliminary fmdings. 
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